Support for research on retroviral pathogenesis, treatment and prevention

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201000003C
Awardee
Awarding agency
Obligated
$4,286,831

Award facts

Opportunity
Contract value 91% obligated
  • $4,286,831.49 Current, with exercised options
  • $4,712,200.49 Potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 2 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Kensington, MD 20895, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00018 -$11
Other Administrative Action P00017 -$289
Other Administrative Action 16 -$724
Other Administrative Action 15 · Title: support for research on retroviral pathogenesis, treatment and prevention -$23,811
Exercise an Option 14 $130,000
Funding Only Action 13 $82,844
Other Administrative Action 12 $0
Funding Only Action 11 $642,238
Other Administrative Action 10 · Other functions $72,398
Exercise an Option 9 $1,220,000
Exercise an Option 8 · Other functions the purpose of this modification is to exercise option 7, year 4, and add FY13 funding. $1,174,000
Other Administrative Action 7 $0
Funding Only Action 6 $400,000
Funding Only Action 5 · The purpose of this modification is to exercise option 2, year 3, and add FY12 incremental funding. $570,000
Exercise an Option 4 · The purpose of this modifiation is to exercise option 2 year 3 and incrementally fund with FY12 funds. $840,000
Funding Only Action 3 · The purpose of this modification is to add FY11 incremental funding. $400,000
Funding Only Action 2 · The purpose of this modification is to provide incremental funding $400,000
Exercise an Option 1 · The purpose of this modifiation is to exercise option 1. -$2,523,328
Original award $903,514
Show all 19

About this award

Written by GovTribe AI ·

This is a definitive contract awarded by the National Cancer Institute (NCI), a part of the Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned, for-profit manufacturer of goods. The $4,712,200.49 cost-plus-fixed-fee contract supports research on retroviral pathogenesis, treatment, and prevention. It has an ultimate completion date of November 30, 2014 and does not have a set-aside designation.

ABL has significant expertise in biologics manufacturing, testing, and quality assurance services, and has been awarded numerous federal contracts and grants, particularly from the NIH and HHS, to advance the development of medical countermeasures. This contract is part of ABL's broader portfolio of Indefinite Delivery Vehicles (IDVs) with federal agencies, including with the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Neurological Disorders and Stroke (NINDS), which demonstrate the company's comprehensive capabilities in supporting the development of vaccines, therapeutics, and diagnostics across multiple disease areas.

Quick answers

Who was awarded contract HHSN261201000003C?

HHSN261201000003C was awarded to Advanced Bioscience Laboratories, Inc. by National Cancer Institute (National Institutes of Health) on November 1, 2009.

How much is contract HHSN261201000003C worth?

The government has obligated $4,286,831 on HHSN261201000003C. Its potential value, with all options, is $4,712,200.

Was contract HHSN261201000003C competed?

The extent of competition for HHSN261201000003C was full and open competition. The government received 2 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login